Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15551 - 15575 of 15760 in total
Henatinib has been used in trials studying the treatment of Advanced Solid Cancer.
Investigational
Matched Iupac: … (3Z)-5-fluoro-3-({5-[(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]-3-methyl-4-oxo-1H,4H,5H,6H,7H,8H-pyrrolo …
Investigational
Matched Iupac: … )-4,6-diamino-3-{[(2R,3R,6S)-3-amino-6-[(1R)-1-aminoethyl]oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl
BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
Investigational
Matched Description: … BF-37 for the treatment of atopic dermatitis and/or psoriasis. …
ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR). It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping control type 2 diabetes.
Investigational
Matched Description: … clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and
Linopristin is an antibiotic of the streptogramin B class. It is one part of the combination product NXL 103, along with Virginiamycin M1. The combination product was under investigation in clinical trials NCT00653172 and NCT00949130 for treatment of various bacterial infections.
Investigational
Matched Description: … The combination product was under investigation in clinical trials NCT00653172 and NCT00949130 for treatment …
Iguratimod is under investigation in Rheumatoid Arthritis.
Investigational
Experimental
Illicit
Experimental
Experimental
Matched Iupac: … (8E)-9-[(1R,12R,15S,18S,20S,22R,30S,31S)-20-hydroxy-18-methyl-13,16,37-trioxo-2,10,17,28,29,36-hexaoxa …
GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
Investigational
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Description: … is developing as a treatment for allergic reactions of the skin, such as those associated with hives and
Investigational
Matched Iupac: … 6,13-bis[3-(morpholin-4-yl)propyl]-2-{[2-(pyrrolidin-1-yl)ethyl]amino}-9-{4-[(pyrrolidin-1-yl)methyl] …
Ammonium molybdate is a source of molybdenum that exists in several hydrate forms. It is intravenously administered as an additive to solutions for Total Parenteral Nutrition (TPN). Molybdenum is an essential element that is present in enzymes including xanthine oxidase, sulfite oxidase, and aldehyde oxidase.
Experimental
Matched Description: … Molybdenum is an essential element that is present in enzymes including xanthine oxidase, sulfite oxidase, and
Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene. Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining stable hemodynamics. Its use was ultimately limited because it was highly explosive.
Experimental
Matched Description: … Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining …
Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational
BO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-angioplasty Blood Vessel Re-closure (Restenosis) in Stented Vessels.).
Investigational
Matched Description: … Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Description: … anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and
Displaying drugs 15551 - 15575 of 15760 in total